281 related articles for article (PubMed ID: 33556450)
1. Management of a Prostate Cancer Patient With Inherited Germline BRCA1 and BRCA2 Mutations: A Case Report.
Hemal S; DeWitt-Foy M; Klein EA
Urology; 2021 Jul; 153():129-131. PubMed ID: 33556450
[TBL] [Abstract][Full Text] [Related]
2. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.
Castro E; Goh C; Olmos D; Saunders E; Leongamornlert D; Tymrakiewicz M; Mahmud N; Dadaev T; Govindasami K; Guy M; Sawyer E; Wilkinson R; Ardern-Jones A; Ellis S; Frost D; Peock S; Evans DG; Tischkowitz M; Cole T; Davidson R; Eccles D; Brewer C; Douglas F; Porteous ME; Donaldson A; Dorkins H; Izatt L; Cook J; Hodgson S; Kennedy MJ; Side LE; Eason J; Murray A; Antoniou AC; Easton DF; Kote-Jarai Z; Eeles R
J Clin Oncol; 2013 May; 31(14):1748-57. PubMed ID: 23569316
[TBL] [Abstract][Full Text] [Related]
3. Prostate Cancer Screening in a New Era of Genetics.
Cheng HH; Pritchard CC; Montgomery B; Lin DW; Nelson PS
Clin Genitourin Cancer; 2017 Dec; 15(6):625-628. PubMed ID: 28697982
[TBL] [Abstract][Full Text] [Related]
4. Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer.
Castro E; Goh C; Leongamornlert D; Saunders E; Tymrakiewicz M; Dadaev T; Govindasami K; Guy M; Ellis S; Frost D; Bancroft E; Cole T; Tischkowitz M; Kennedy MJ; Eason J; Brewer C; Evans DG; Davidson R; Eccles D; Porteous ME; Douglas F; Adlard J; Donaldson A; Antoniou AC; Kote-Jarai Z; Easton DF; Olmos D; Eeles R
Eur Urol; 2015 Aug; 68(2):186-93. PubMed ID: 25454609
[TBL] [Abstract][Full Text] [Related]
5. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.
Bancroft EK; Page EC; Castro E; Lilja H; Vickers A; Sjoberg D; Assel M; Foster CS; Mitchell G; Drew K; Mæhle L; Axcrona K; Evans DG; Bulman B; Eccles D; McBride D; van Asperen C; Vasen H; Kiemeney LA; Ringelberg J; Cybulski C; Wokolorczyk D; Selkirk C; Hulick PJ; Bojesen A; Skytte AB; Lam J; Taylor L; Oldenburg R; Cremers R; Verhaegh G; van Zelst-Stams WA; Oosterwijk JC; Blanco I; Salinas M; Cook J; Rosario DJ; Buys S; Conner T; Ausems MG; Ong KR; Hoffman J; Domchek S; Powers J; Teixeira MR; Maia S; Foulkes WD; Taherian N; Ruijs M; Helderman-van den Enden AT; Izatt L; Davidson R; Adank MA; Walker L; Schmutzler R; Tucker K; Kirk J; Hodgson S; Harris M; Douglas F; Lindeman GJ; Zgajnar J; Tischkowitz M; Clowes VE; Susman R; Ramón y Cajal T; Patcher N; Gadea N; Spigelman A; van Os T; Liljegren A; Side L; Brewer C; Brady AF; Donaldson A; Stefansdottir V; Friedman E; Chen-Shtoyerman R; Amor DJ; Copakova L; Barwell J; Giri VN; Murthy V; Nicolai N; Teo SH; Greenhalgh L; Strom S; Henderson A; McGrath J; Gallagher D; Aaronson N; Ardern-Jones A; Bangma C; Dearnaley D; Costello P; Eyfjord J; Rothwell J; Falconer A; Gronberg H; Hamdy FC; Johannsson O; Khoo V; Kote-Jarai Z; Lubinski J; Axcrona U; Melia J; McKinley J; Mitra AV; Moynihan C; Rennert G; Suri M; Wilson P; Killick E; ; Moss S; Eeles RA
Eur Urol; 2014 Sep; 66(3):489-99. PubMed ID: 24484606
[TBL] [Abstract][Full Text] [Related]
6. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers.
Page EC; Bancroft EK; Brook MN; Assel M; Hassan Al Battat M; Thomas S; Taylor N; Chamberlain A; Pope J; Raghallaigh HN; Evans DG; Rothwell J; Maehle L; Grindedal EM; James P; Mascarenhas L; McKinley J; Side L; Thomas T; van Asperen C; Vasen H; Kiemeney LA; Ringelberg J; Jensen TD; Osther PJS; Helfand BT; Genova E; Oldenburg RA; Cybulski C; Wokolorczyk D; Ong KR; Huber C; Lam J; Taylor L; Salinas M; Feliubadaló L; Oosterwijk JC; van Zelst-Stams W; Cook J; Rosario DJ; Domchek S; Powers J; Buys S; O'Toole K; Ausems MGEM; Schmutzler RK; Rhiem K; Izatt L; Tripathi V; Teixeira MR; Cardoso M; Foulkes WD; Aprikian A; van Randeraad H; Davidson R; Longmuir M; Ruijs MWG; Helderman van den Enden ATJM; Adank M; Williams R; Andrews L; Murphy DG; Halliday D; Walker L; Liljegren A; Carlsson S; Azzabi A; Jobson I; Morton C; Shackleton K; Snape K; Hanson H; Harris M; Tischkowitz M; Taylor A; Kirk J; Susman R; Chen-Shtoyerman R; Spigelman A; Pachter N; Ahmed M; Ramon Y Cajal T; Zgajnar J; Brewer C; Gadea N; Brady AF; van Os T; Gallagher D; Johannsson O; Donaldson A; Barwell J; Nicolai N; Friedman E; Obeid E; Greenhalgh L; Murthy V; Copakova L; Saya S; McGrath J; Cooke P; Rønlund K; Richardson K; Henderson A; Teo SH; Arun B; Kast K; Dias A; Aaronson NK; Ardern-Jones A; Bangma CH; Castro E; Dearnaley D; Eccles DM; Tricker K; Eyfjord J; Falconer A; Foster C; Gronberg H; Hamdy FC; Stefansdottir V; Khoo V; Lindeman GJ; Lubinski J; Axcrona K; Mikropoulos C; Mitra A; Moynihan C; Rennert G; Suri M; Wilson P; Dudderidge T; ; Offman J; Kote-Jarai Z; Vickers A; Lilja H; Eeles RA
Eur Urol; 2019 Dec; 76(6):831-842. PubMed ID: 31537406
[TBL] [Abstract][Full Text] [Related]
7. Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population.
Petrovics G; Price DK; Lou H; Chen Y; Garland L; Bass S; Jones K; Kohaar I; Ali A; Ravindranath L; Young D; Cullen J; Dorsey TH; Sesterhenn IA; Brassell SA; Rosner IL; Ross D; Dahut W; Ambs S; Figg WD; Srivastava S; Dean M
Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):406-410. PubMed ID: 30542053
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations.
Rajwa P; Quhal F; Pradere B; Gandaglia G; Ploussard G; Leapman MS; Gore JL; Paradysz A; Tilki D; Merseburger AS; Morgan TM; Briganti A; Palapattu GS; Shariat SF
Nat Rev Urol; 2023 Apr; 20(4):205-216. PubMed ID: 36600087
[TBL] [Abstract][Full Text] [Related]
9. Male BRCA mutation carriers: clinical characteristics and cancer spectrum.
Ibrahim M; Yadav S; Ogunleye F; Zakalik D
BMC Cancer; 2018 Feb; 18(1):179. PubMed ID: 29433453
[TBL] [Abstract][Full Text] [Related]
10. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
Hamel N; Kotar K; Foulkes WD
BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
[TBL] [Abstract][Full Text] [Related]
11. Screening, Active Surveillance, and Treatment of Localized Prostate Cancer Among Carriers of Germline BRCA Mutations.
Halstuch D; Ber Y; Margel D
Eur Urol Focus; 2020 Mar; 6(2):212-214. PubMed ID: 31147265
[TBL] [Abstract][Full Text] [Related]
12. Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.
Na R; Zheng SL; Han M; Yu H; Jiang D; Shah S; Ewing CM; Zhang L; Novakovic K; Petkewicz J; Gulukota K; Helseth DL; Quinn M; Humphries E; Wiley KE; Isaacs SD; Wu Y; Liu X; Zhang N; Wang CH; Khandekar J; Hulick PJ; Shevrin DH; Cooney KA; Shen Z; Partin AW; Carter HB; Carducci MA; Eisenberger MA; Denmeade SR; McGuire M; Walsh PC; Helfand BT; Brendler CB; Ding Q; Xu J; Isaacs WB
Eur Urol; 2017 May; 71(5):740-747. PubMed ID: 27989354
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.
Mikropoulos C; Selkirk CGH; Saya S; Bancroft E; Vertosick E; Dadaev T; Brendler C; Page E; Dias A; Evans DG; Rothwell J; Maehle L; Axcrona K; Richardson K; Eccles D; Jensen T; Osther PJ; van Asperen CJ; Vasen H; Kiemeney LA; Ringelberg J; Cybulski C; Wokolorczyk D; Hart R; Glover W; Lam J; Taylor L; Salinas M; Feliubadaló L; Oldenburg R; Cremers R; Verhaegh G; van Zelst-Stams WA; Oosterwijk JC; Cook J; Rosario DJ; Buys SS; Conner T; Domchek S; Powers J; Ausems MG; Teixeira MR; Maia S; Izatt L; Schmutzler R; Rhiem K; Foulkes WD; Boshari T; Davidson R; Ruijs M; Helderman-van den Enden AT; Andrews L; Walker L; Snape K; Henderson A; Jobson I; Lindeman GJ; Liljegren A; Harris M; Adank MA; Kirk J; Taylor A; Susman R; Chen-Shtoyerman R; Pachter N; Spigelman A; Side L; Zgajnar J; Mora J; Brewer C; Gadea N; Brady AF; Gallagher D; van Os T; Donaldson A; Stefansdottir V; Barwell J; James PA; Murphy D; Friedman E; Nicolai N; Greenhalgh L; Obeid E; Murthy V; Copakova L; McGrath J; Teo SH; Strom S; Kast K; Leongamornlert DA; Chamberlain A; Pope J; Newlin AC; Aaronson N; Ardern-Jones A; Bangma C; Castro E; Dearnaley D; Eyfjord J; Falconer A; Foster CS; Gronberg H; Hamdy FC; Johannsson O; Khoo V; Lubinski J; Grindedal EM; McKinley J; Shackleton K; Mitra AV; Moynihan C; Rennert G; Suri M; Tricker K; ; Moss S; Kote-Jarai Z; Vickers A; Lilja H; Helfand BT; Eeles RA
Br J Cancer; 2018 Jan; 118(2):266-276. PubMed ID: 29301143
[TBL] [Abstract][Full Text] [Related]
14. Initial Findings from a High Genetic Risk Prostate Cancer Clinic.
Sessine MS; Das S; Park B; Salami SS; Kaffenberger SD; Kasputis A; Solorzano M; Luke M; Vince RA; Kaye DR; Borza T; Stoffel EM; Cobain E; Merajver SD; Jacobs MF; Milliron KJ; Caba L; van Neste L; Mondul AM; Morgan TM
Urology; 2021 Oct; 156():96-103. PubMed ID: 34280438
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive Proteomic Profiling-derived Immunohistochemistry-based Prediction Models for BRCA1 and BRCA2 Germline Mutation-related Breast Carcinomas.
Vos S; Elias SG; van der Groep P; Smolders YH; van Gils CH; van Diest PJ
Am J Surg Pathol; 2018 Sep; 42(9):1262-1272. PubMed ID: 29979200
[TBL] [Abstract][Full Text] [Related]
16. Association of Genomic Domains in
Patel VL; Busch EL; Friebel TM; Cronin A; Leslie G; McGuffog L; Adlard J; Agata S; Agnarsson BA; Ahmed M; Aittomäki K; Alducci E; Andrulis IL; Arason A; Arnold N; Artioli G; Arver B; Auber B; Azzollini J; Balmaña J; Barkardottir RB; Barnes DR; Barroso A; Barrowdale D; Belotti M; Benitez J; Bertelsen B; Blok MJ; Bodrogi I; Bonadona V; Bonanni B; Bondavalli D; Boonen SE; Borde J; Borg A; Bradbury AR; Brady A; Brewer C; Brunet J; Buecher B; Buys SS; Cabezas-Camarero S; Caldés T; Caliebe A; Caligo MA; Calvello M; Campbell IG; Carnevali I; Carrasco E; Chan TL; Chu ATW; Chung WK; Claes KBM; Collaborators GS; Collaborators E; Cook J; Cortesi L; Couch FJ; Daly MB; Damante G; Darder E; Davidson R; de la Hoya M; Puppa LD; Dennis J; Díez O; Ding YC; Ditsch N; Domchek SM; Donaldson A; Dworniczak B; Easton DF; Eccles DM; Eeles RA; Ehrencrona H; Ejlertsen B; Engel C; Evans DG; Faivre L; Faust U; Feliubadaló L; Foretova L; Fostira F; Fountzilas G; Frost D; García-Barberán V; Garre P; Gauthier-Villars M; Géczi L; Gehrig A; Gerdes AM; Gesta P; Giannini G; Glendon G; Godwin AK; Goldgar DE; Greene MH; Gutierrez-Barrera AM; Hahnen E; Hamann U; Hauke J; Herold N; Hogervorst FBL; Honisch E; Hopper JL; Hulick PJ; Investigators K; Investigators H; Izatt L; Jager A; James P; Janavicius R; Jensen UB; Jensen TD; Johannsson OT; John EM; Joseph V; Kang E; Kast K; Kiiski JI; Kim SW; Kim Z; Ko KP; Konstantopoulou I; Kramer G; Krogh L; Kruse TA; Kwong A; Larsen M; Lasset C; Lautrup C; Lazaro C; Lee J; Lee JW; Lee MH; Lemke J; Lesueur F; Liljegren A; Lindblom A; Llovet P; Lopez-Fernández A; Lopez-Perolio I; Lorca V; Loud JT; Ma ESK; Mai PL; Manoukian S; Mari V; Martin L; Matricardi L; Mebirouk N; Medici V; Meijers-Heijboer HEJ; Meindl A; Mensenkamp AR; Miller C; Gomes DM; Montagna M; Mooij TM; Moserle L; Mouret-Fourme E; Mulligan AM; Nathanson KL; Navratilova M; Nevanlinna H; Niederacher D; Nielsen FCC; Nikitina-Zake L; Offit K; Olah E; Olopade OI; Ong KR; Osorio A; Ott CE; Palli D; Park SK; Parsons MT; Pedersen IS; Peissel B; Peixoto A; Pérez-Segura P; Peterlongo P; Petersen AH; Porteous ME; Pujana MA; Radice P; Ramser J; Rantala J; Rashid MU; Rhiem K; Rizzolo P; Robson ME; Rookus MA; Rossing CM; Ruddy KJ; Santos C; Saule C; Scarpitta R; Schmutzler RK; Schuster H; Senter L; Seynaeve CM; Shah PD; Sharma P; Shin VY; Silvestri V; Simard J; Singer CF; Skytte AB; Snape K; Solano AR; Soucy P; Southey MC; Spurdle AB; Steele L; Steinemann D; Stoppa-Lyonnet D; Stradella A; Sunde L; Sutter C; Tan YY; Teixeira MR; Teo SH; Thomassen M; Tibiletti MG; Tischkowitz M; Tognazzo S; Toland AE; Tommasi S; Torres D; Toss A; Trainer AH; Tung N; van Asperen CJ; van der Baan FH; van der Kolk LE; van der Luijt RB; van Hest LP; Varesco L; Varon-Mateeva R; Viel A; Vierstraete J; Villa R; von Wachenfeldt A; Wagner P; Wang-Gohrke S; Wappenschmidt B; Weitzel JN; Wieme G; Yadav S; Yannoukakos D; Yoon SY; Zanzottera C; Zorn KK; D'Amico AV; Freedman ML; Pomerantz MM; Chenevix-Trench G; Antoniou AC; Neuhausen SL; Ottini L; Nielsen HR; Rebbeck TR
Cancer Res; 2020 Feb; 80(3):624-638. PubMed ID: 31723001
[TBL] [Abstract][Full Text] [Related]
17. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis.
Oh M; Alkhushaym N; Fallatah S; Althagafi A; Aljadeed R; Alsowaida Y; Jeter J; Martin JR; Babiker HM; McBride A; Abraham I
Prostate; 2019 Jun; 79(8):880-895. PubMed ID: 30900310
[TBL] [Abstract][Full Text] [Related]
18. The role of BRCA1 and BRCA2 in prostate cancer.
Castro E; Eeles R
Asian J Androl; 2012 May; 14(3):409-14. PubMed ID: 22522501
[TBL] [Abstract][Full Text] [Related]
19. Germline BRCA mutation in male carriers-ripe for precision oncology?
Leão RRN; Price AJ; James Hamilton R
Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):48-56. PubMed ID: 29242595
[TBL] [Abstract][Full Text] [Related]
20. Personalized prostate cancer screening among men with high risk genetic predisposition- study protocol for a prospective cohort study.
Margel D; Benjaminov O; Ozalvo R; Shavit Grievink L; Kedar I; Yerushalmi R; Ben-Aharon I; Neiman V; Yossepowitch O; Kedar D; Levy Z; Shohat M; Brenner B; Baniel J; Rosenbaum E
BMC Cancer; 2014 Jul; 14():528. PubMed ID: 25047061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
